Adherium bundles debt into $3.3M term loan from top shareholder Trudell
What's the deal? AdheriumDealroom has a profile for this one. Try Dealroom →, an ASX-listed maker of connected respiratory devices, has consolidated its borrowings into a single US$3.02M (roughly $3.3 million) term loan from its major shareholder, Trudell Medical LimitedDealroom has a profile for this one. Try Dealroom →. The Melbourne-based company announced the arrangement on September 16, 2026.
The details: Trudell added US$841.2K in new funding and rolled it together with earlier short-term loans — $1,650,000 from June and US$647.1K from August — plus accrued interest. The unsecured loan carries 12% annual interest, capitalised monthly, and is due August 31, 2027.
What Adherium does: It develops the Hailie Smartinhaler, a US FDA-cleared device that lets clinicians and patients track medication use remotely. The company says it has sold more than 180,000 connected respiratory devices worldwide.
Why now? The money covers working capital. Adherium said third-party financing was "limited, uncertain, or available only on terms that are materially less favourable," and that the Trudell loan avoids diluting existing shareholders while meeting immediate needs.
What could go wrong? The loan becomes repayable immediately on any event of default, and the string of short-term borrowings points to persistent cash pressure. Board member George Baran, who is tied to Trudell, abstained from the decision.
The signal: A quick re-raise from an insider — three loans consolidated within months — shows a small-cap medtech leaning on its largest backer to stay funded. For a company with FDA clearance but tight cash, patient capital from a strategic shareholder can bridge the gap where the open market will not.
Read more: listcorp.com
Image credit: Generated with Gemini
